vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Civeo Corp (CVEO). Click either name above to swap in a different company.
Civeo Corp is the larger business by last-quarter revenue ($161.6M vs $139.2M, roughly 1.2× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -4.0%, a 39.5% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 7.1%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $14.5M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -1.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.
ADMA vs CVEO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $161.6M |
| Net Profit | $49.4M | $-6.5M |
| Gross Margin | 63.8% | 22.7% |
| Operating Margin | 45.1% | -0.1% |
| Net Margin | 35.5% | -4.0% |
| Revenue YoY | 18.4% | 7.1% |
| Net Profit YoY | -55.9% | 58.1% |
| EPS (diluted) | $0.20 | $-0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $161.6M | ||
| Q3 25 | $134.2M | $170.5M | ||
| Q2 25 | $122.0M | $162.7M | ||
| Q1 25 | $114.8M | $144.0M | ||
| Q4 24 | $117.5M | $151.0M | ||
| Q3 24 | $119.8M | $176.3M | ||
| Q2 24 | $107.2M | $188.7M | ||
| Q1 24 | $81.9M | $166.1M |
| Q4 25 | $49.4M | $-6.5M | ||
| Q3 25 | $36.4M | $-455.0K | ||
| Q2 25 | $34.2M | $-3.3M | ||
| Q1 25 | $26.9M | $-9.8M | ||
| Q4 24 | $111.9M | $-15.4M | ||
| Q3 24 | $35.9M | $-5.1M | ||
| Q2 24 | $32.1M | $8.2M | ||
| Q1 24 | $17.8M | $-5.1M |
| Q4 25 | 63.8% | 22.7% | ||
| Q3 25 | 56.3% | 25.7% | ||
| Q2 25 | 55.1% | 25.3% | ||
| Q1 25 | 53.2% | 20.4% | ||
| Q4 24 | 53.9% | 18.6% | ||
| Q3 24 | 49.8% | 21.4% | ||
| Q2 24 | 53.6% | 25.4% | ||
| Q1 24 | 47.8% | 21.5% |
| Q4 25 | 45.1% | -0.1% | ||
| Q3 25 | 38.0% | 4.1% | ||
| Q2 25 | 35.1% | 1.7% | ||
| Q1 25 | 30.4% | -3.8% | ||
| Q4 24 | 32.6% | -6.7% | ||
| Q3 24 | 33.1% | 0.0% | ||
| Q2 24 | 36.6% | 6.9% | ||
| Q1 24 | 26.7% | -1.1% |
| Q4 25 | 35.5% | -4.0% | ||
| Q3 25 | 27.1% | -0.3% | ||
| Q2 25 | 28.1% | -2.0% | ||
| Q1 25 | 23.4% | -6.8% | ||
| Q4 24 | 95.2% | -10.2% | ||
| Q3 24 | 30.0% | -2.9% | ||
| Q2 24 | 29.9% | 4.4% | ||
| Q1 24 | 21.7% | -3.1% |
| Q4 25 | $0.20 | $-0.58 | ||
| Q3 25 | $0.15 | $-0.04 | ||
| Q2 25 | $0.14 | $-0.25 | ||
| Q1 25 | $0.11 | $-0.72 | ||
| Q4 24 | $0.45 | $-1.04 | ||
| Q3 24 | $0.15 | $-0.36 | ||
| Q2 24 | $0.13 | $0.56 | ||
| Q1 24 | $0.08 | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $14.4M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $174.4M |
| Total Assets | $624.2M | $477.4M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $14.4M | ||
| Q3 25 | $61.4M | $12.0M | ||
| Q2 25 | $90.3M | $14.6M | ||
| Q1 25 | $71.6M | $28.4M | ||
| Q4 24 | $103.1M | $5.2M | ||
| Q3 24 | $86.7M | $17.9M | ||
| Q2 24 | $88.2M | $7.4M | ||
| Q1 24 | $45.3M | $16.8M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | $43.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $174.4M | ||
| Q3 25 | $431.2M | $182.5M | ||
| Q2 25 | $398.3M | $209.4M | ||
| Q1 25 | $373.4M | $220.7M | ||
| Q4 24 | $349.0M | $236.4M | ||
| Q3 24 | $231.9M | $282.2M | ||
| Q2 24 | $188.3M | $297.4M | ||
| Q1 24 | $153.7M | $297.4M |
| Q4 25 | $624.2M | $477.4M | ||
| Q3 25 | $568.7M | $491.1M | ||
| Q2 25 | $558.4M | $508.8M | ||
| Q1 25 | $510.6M | $423.8M | ||
| Q4 24 | $488.7M | $405.1M | ||
| Q3 24 | $390.6M | $477.6M | ||
| Q2 24 | $376.4M | $483.2M | ||
| Q1 24 | $350.9M | $513.1M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 0.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $19.3M |
| Free Cash FlowOCF − Capex | $34.6M | $14.5M |
| FCF MarginFCF / Revenue | 24.8% | 8.9% |
| Capex IntensityCapex / Revenue | 0.8% | 3.0% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $19.3M | ||
| Q3 25 | $13.3M | $13.8M | ||
| Q2 25 | $21.1M | $-2.3M | ||
| Q1 25 | $-19.7M | $-8.4M | ||
| Q4 24 | $50.2M | $9.5M | ||
| Q3 24 | $25.0M | $35.7M | ||
| Q2 24 | $45.6M | $32.4M | ||
| Q1 24 | $-2.2M | $6.0M |
| Q4 25 | $34.6M | $14.5M | ||
| Q3 25 | $-1.1M | $8.2M | ||
| Q2 25 | $18.7M | $-6.8M | ||
| Q1 25 | $-24.4M | $-13.7M | ||
| Q4 24 | $47.5M | $1.8M | ||
| Q3 24 | $24.0M | $28.2M | ||
| Q2 24 | $43.6M | $27.0M | ||
| Q1 24 | $-4.6M | $372.0K |
| Q4 25 | 24.8% | 8.9% | ||
| Q3 25 | -0.8% | 4.8% | ||
| Q2 25 | 15.3% | -4.2% | ||
| Q1 25 | -21.2% | -9.5% | ||
| Q4 24 | 40.4% | 1.2% | ||
| Q3 24 | 20.0% | 16.0% | ||
| Q2 24 | 40.7% | 14.3% | ||
| Q1 24 | -5.6% | 0.2% |
| Q4 25 | 0.8% | 3.0% | ||
| Q3 25 | 10.7% | 3.3% | ||
| Q2 25 | 2.0% | 2.8% | ||
| Q1 25 | 4.1% | 3.7% | ||
| Q4 24 | 2.3% | 5.1% | ||
| Q3 24 | 0.9% | 4.2% | ||
| Q2 24 | 1.9% | 2.8% | ||
| Q1 24 | 2.9% | 3.4% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | 3.93× | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
CVEO
Segment breakdown not available.
